Is this a Prime Time To acquire Pacific Biosciences of California Inc. (PACB) stock

In other words, the price has increased by $0.00 from its previous closing price. On the day, 3912227 shares were traded. PACB stock price reached its highest trading level at $11.49 during the session, while it also had its lowest trading level at $10.82.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



Our goal is to gain a better understanding of PACB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.70 and its Current Ratio is at 11.20. In the meantime, Its Debt-to-Equity ratio is 1.43 whereas as Long-Term Debt/Eq ratio is at 1.43.

Upgrades & Downgrades

On January 05, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $12.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 10 when Van Oene Mark sold 26,722 shares for $9.53 per share. The transaction valued at 254,768 led to the insider holds 640,808 shares of the business.

HENRY CHRISTIAN O sold 45,000 shares of PACB for $487,980 on Dec 01. The insider now owns 643,551 shares after completing the transaction at $10.84 per share. On Sep 29, another insider, Kim Susan G., who serves as the insider of the company, sold 12,968 shares for $5.61 each. As a result, the insider received 72,802 and left with 163,488 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 18.63 while its Price-to-Book (P/B) ratio in mrq is 4.06.

Stock Price History:

Over the past 52 weeks, PACB has reached a high of $14.20, while it has fallen to a 52-week low of $3.85. The 50-Day Moving Average of the stock is 9.72, while the 200-Day Moving Average is calculated to be 6.99.

Shares Statistics:

The stock has traded on average 4.87M shares per day over the past 3-months and 4.25M shares per day over the last 10 days, according to various share statistics. A total of 225.12M shares are outstanding, with a floating share count of 206.29M. Insiders hold about 0.80% of the company’s shares, while institutions hold 88.90% stake in the company. Shares short for PACB as of Oct 13, 2022 were 23.95M with a Short Ratio of 24.67M, compared to 30.31M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 10.65% and a Short% of Float of 13.63%.

Earnings Estimates

Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.33 for the current quarter, with a high estimate of -$0.31 and a low estimate of -$0.36, while EPS last year was $0.08. The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.31 and low estimates of -$0.37.

Analysts are recommending an EPS of between -$1.31 and -$1.4 for the fiscal current year, implying an average EPS of -$1.37. EPS for the following year is -$1.34, with 6 analysts recommending between -$1.13 and -$1.57.

Revenue Estimates

5 analysts predict $35.4M in revenue for the current quarter. It ranges from a high estimate of $35.8M to a low estimate of $34.8M. As of the current estimate, Pacific Biosciences of California Inc.’s year-ago sales were $34.89M, an estimated increase of 1.50% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $37.62M, an increase of 4.40% over than the figure of $1.50% in the same quarter last year. There is a high estimate of $38.3M for the next quarter, whereas the lowest estimate is $37M.

A total of 6 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $142.6M, while the lowest revenue estimate was $140M, resulting in an average revenue estimate of $141.72M. In the same quarter a year ago, actual revenue was $130.51M, up 8.60% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $182.89M in the next fiscal year. The high estimate is $205.3M and the low estimate is $170M. The average revenue growth estimate for next year is up 29.10% from the average revenue estimate for this year.